| Citation: | Branch of Organ Transplantation of Chinese Medical Association. Diagnosis and treatment specifcation for hepatitis C virus infection after organ transplantation (2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(3): 249-252. doi: 10.3969/j.issn.1674-7445.2019.03.005
|
| [1] |
LANINI S, PISAPIA R, CAPOBIANCHI MR, et al. Global epidemiology of viral hepatitis and national needs for complete control[J]. Expert Rev Anti Infect Ther, 2018, 16(8):625-639. DOI: 10.1080/14787210.2018.1505503.
|
| [2] |
苏迎盈, 刘慧鑫, 汪宁.中国丙型肝炎病毒基因型分布[J].中华流行病学杂志, 2013, 34(1):80-84. DOI: 10.3760/cma.j.issn.0254-6450.2013.01.019.
SUN YY, LIU HX, WANG N. Hepatitis C virus genotypes in China: a systematic review[J]. Chin J Epidemiol, 2013, 34(1):80-84.DOI: 10.3760/cma.j.issn.0254-6450.2013.01.019.
|
| [3] |
WONG MCS, HUANG JLW, GEORGE J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(1):57-73. DOI: 10.1038/s41575-018-0055-0.
|
| [4] |
陈园生, 李黎, 崔富强, 等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志, 2011, 32(9):888-891. DOI: 10.3760/cma.j.issn.0254-6450.2011.09.009.
CHEN YS, LI L, CUI FQ, et al. A sero-epidemiological study on hepatitis C in China[J]. Chin J Epidemiol, 2011, 32(9):888-891.DOI: 10.3760/cma.j.issn.0254-6450.2011.09.009.
|
| [5] |
COILLY A, ROCHE B, SAMUEL D. Current management and perspectives for HCV recurrence after liver transplantation[J].Liver Int, 2013, 33(Suppl 1):56-62. DOI: 10.1111/liv.12062.
|
| [6] |
DOMÍNGUEZ-GIL B, MORALES JM. Transplantation in the patient with hepatitis C[J]. Transpl Int, 2009, 22(12):1117-1131. DOI: 10.1111/j.1432-2277.2009.00926.x.
|
| [7] |
FORMAN LM, LEWIS JD, BERLIN JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation[J]. Gastroenterology, 2002, 122(4):889-896. doi: 10.1053/gast.2002.32418
|
| [8] |
HEIDRICH B, PISCHKE S, HELFRITZ FA, et al. Hepatitis C virus core antigen testing in liver and kidney transplant recipients[J]. J Viral Hepat, 2014, 21(11):769-779. DOI: 10.1111/jvh.12204.
|
| [9] |
ALONSO R, PÉREZ-GARCÍA F, LÓPEZ-ROA P, et al. HCV core-antigen assay as an alternative to HCV RNA quantification: a correlation study for the assessment of HCV viremia[J]. Enferm Infecc Microbiol Clin, 2018, 36(3):175-178. DOI: 10.1016/j.eimc.2016.11.013.
|
| [10] |
FABRIZI F, AGHEMO A, MESSA P. Hepatitis C treatment in patients with kidney disease[J]. Kidney Int, 2013, 84(5):874-879. DOI: 10.1038/ki.2013.264.
|
| [11] |
BURRA P, RODRÍGUEZ-CASTRO KI, MARCHINI F, et al. Hepatitis C virus infection in end-stage renal disease and kidney transplantation[J]. Transpl Int, 2014, 27(9):877-891. DOI: 10.1111/tri.12360.
|
| [12] |
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease[J]. Kidney Int Suppl, 2008(109):S1-S99. DOI: 10.1038/ki.2008.81.
|
| [13] |
CIESEK S, PROSKE V, OTTO B, et al. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation[J].Transpl Infect Dis, 2016, 18(3):326-332. DOI: 10.1111/tid.12524.
|
| [14] |
TERRAULT NA, STOCK PG. Management of hepatitis C in kidney transplant patients: on the cusp of change[J]. Am J Transplant, 2014, 14(9):1955-1957. DOI: 10.1111/ajt.12848.
|
| [15] |
LIN MV, SISE ME, PAVLAKIS M, et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection[J]. PLoS One, 2016, 11(7):e0158431. DOI: 10.1371/journal.pone.0158431.
|
| [16] |
KIEFFER TL, SARRAZIN C, MILLER JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients[J]. Hepatology, 2007, 46(3):631-639. doi: 10.1002/hep.v46:3
|
| [17] |
FABRIZI F, MARTIN P, MESSA P. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant[J]. Kidney Int, 2016, 89(5):988-994. DOI: 10.1016/j.kint.2016.01.011.
|
| [18] |
MORALES JM, FABRIZI F. Hepatitis C and its impact on renal transplantation[J]. Nat Rev Nephrol, 2015, 11(3):172-182. DOI: 10.1038/nrneph.2015.5.
|
| [19] |
Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease[J]. Kidney Int Suppl, 2018, 8(3):91-165. DOI: 10.1016/j.kisu.2018.06.001.
|
| [20] |
XUE W, PAN D, YANG Y, et al. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435[J]. Antiviral Res, 2012, 93(1):126-137. DOI: 10.1016/j.antiviral.2011.11.007.
|
| [21] |
WALKER A, FILKE S, LÜBKE N, et al. Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure[J]. Virol J, 2017, 14(1):106. DOI: 10.1186/s12985-017-0779-4.
|
| [22] |
World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection [M]. Geneva: World Health Organization, 2018: 1-83.
|
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: